Indication creep: physician beware.
作者信息
Hébert Paul C, Stanbrook Matthew
出版信息
CMAJ. 2007 Sep 25;177(7):697, 699. doi: 10.1503/cmaj.071223. Epub 2007 Sep 5.
Abstract
摘要
相似文献
1
Indication creep: physician beware.适应症蔓延：医生需谨慎。
CMAJ. 2007 Sep 25;177(7):697, 699. doi: 10.1503/cmaj.071223. Epub 2007 Sep 5.
2
Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.麻烦的处方：常见药物，隐藏危险。数十人处于危险之中。
Consum Rep. 2006 Jan;71(1):34-9.
3
Reporting adverse effects: a practice to be encouraged.报告不良反应：一项值得鼓励的做法。
Prescrire Int. 2013 Mar;22(136):83.
4
Communicating the risks of medicines: time to move forward.传达药品风险：是时候向前迈进了。
Med Care. 2012 Jun;50(6):463-5. doi: 10.1097/MLR.0b013e31825852f0.
5
[What medicine in gynecology and obstetrics for the future?].[未来妇产科用什么药？]
J Gynecol Obstet Biol Reprod (Paris). 2013 Jun;42(4):305-6. doi: 10.1016/j.jgyn.2013.04.001. Epub 2013 Apr 19.
6
7
Toward improved adverse event/suspected adverse drug reaction reporting.迈向改进不良事件/疑似药物不良反应报告。
Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):89-91. doi: 10.1002/pds.800.
8
Unlicensed and off-label drug use in children.儿童使用未获许可和未按批准说明书用药的情况。
J Postgrad Med. 2005 Oct-Dec;51(4):249-52.
9
Striking the right balance.把握恰当的平衡。
Nat Rev Drug Discov. 2006 Nov;5(11):879. doi: 10.1038/nrd2178.
10
Historical development of pediatric pharmacology.儿科药理学的历史发展。
Handb Exp Pharmacol. 2011;205:v-vi.
引用本文的文献
1
Nonsevere hypertensive disorders of pregnancy and oral antihypertensive medications: an argument in favor of use.非重度妊娠高血压疾病与口服抗高血压药物：支持使用的观点
Am J Obstet Gynecol MFM. 2025 Mar;7(1S):101561. doi: 10.1016/j.ajogmf.2024.101561. Epub 2024 Nov 26.
2
Factor eight inhibitor bypassing activity for refractory bleeding in coronary artery bypass grafting: A propensity-matched analysis.冠状动脉搭桥术中用于难治性出血的凝血因子Ⅷ抑制剂旁路活性：一项倾向匹配分析。
Res Pract Thromb Haemost. 2022 Dec 2;6(8):e12838. doi: 10.1002/rth2.12838. eCollection 2022 Nov.
3
Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.药物标签变更与儿科血液学/肿瘤学处方：衡量美国立法的影响。
Clin Trials. 2021 Dec;18(6):732-740. doi: 10.1177/17407745211030683. Epub 2021 Jul 16.
4
The role of professional societies in limiting indication creep.专业学会在限制适应症扩展方面的作用。
J Gen Intern Med. 2015 Feb;30(2):249-52. doi: 10.1007/s11606-014-2980-0. Epub 2014 Aug 5.
5
Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.钆诱导的肾源性系统性纤维化：一种医源性疾病的兴衰。
Clin Kidney J. 2012 Feb;5(1):82-88. doi: 10.1093/ckj/sfr172.
6
Off-label use of recombinant factor VIIa: why we need better drug monitoring.重组凝血因子VIIa的超说明书用药：为何我们需要更好的药物监测。
CMAJ. 2011 Jan 11;183(1):26-7. doi: 10.1503/cmaj.101842.
7
Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists.成本效益分析和优化药品预算的使用：临床药理学家的关键作用。
Br J Clin Pharmacol. 2010 Sep;70(3):350-5. doi: 10.1111/j.1365-2125.2010.03617.x.
本文引用的文献
1
Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.危重症患者使用促红细胞生成素受体激动剂：一项随机对照试验的荟萃分析
CMAJ. 2007 Sep 25;177(7):725-34. doi: 10.1503/cmaj.071055. Epub 2007 Sep 5.
2
FDA sounds alert on anemia drugs.
JAMA. 2007 May 2;297(17):1868-9. doi: 10.1001/jama.297.17.1868.
3
Safeguarding patient welfare: who's in charge?保障患者福利：谁来负责？
Ann Intern Med. 2006 Aug 15;145(4):305-7. doi: 10.7326/0003-4819-145-4-200608150-00013.
4
Off-label prescribing among office-based physicians.门诊医生的非适应症用药情况。
Arch Intern Med. 2006 May 8;166(9):1021-6. doi: 10.1001/archinte.166.9.1021.
5
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.使用重组人凝血因子VIIa后的血栓栓塞不良事件。
JAMA. 2006 Jan 18;295(3):293-8. doi: 10.1001/jama.295.3.293.
Zotero 插件